These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 16010649)
21. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Winston DJ; Ho WG; Bartoni K; Champlin RE Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988 [TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus infection. Climent C; Vélez R; Capriles JA Bol Asoc Med P R; 1992 Jan; 84(1):31-3. PubMed ID: 1323967 [TBL] [Abstract][Full Text] [Related]
23. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Narvios AB; de Lima M; Shah H; Lichtiger B Bone Marrow Transplant; 2005 Sep; 36(6):499-501. PubMed ID: 16044143 [TBL] [Abstract][Full Text] [Related]
24. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551 [TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks. Bowden RA; Sayers M; Gleaves CA; Banaji M; Newton B; Meyers JD Transfusion; 1987; 27(6):478-81. PubMed ID: 2825381 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Messori A; Rampazzo R; Scroccaro G; Martini N Bone Marrow Transplant; 1994 Feb; 13(2):163-7. PubMed ID: 8205085 [TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients. Brytting M; Mousavi-Jazi M; Boström L; Larsson M; Lunderberg J; Ljungman P; Ringdén O; Sundqvist VA Transplantation; 1995 Nov; 60(9):961-5. PubMed ID: 7491701 [TBL] [Abstract][Full Text] [Related]
28. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009 [TBL] [Abstract][Full Text] [Related]
30. Prevalence of cytomegalovirus antibodies in blood donors at the National Blood Transfusion Centre, Nairobi. Njeru DG; Mwanda WO; Kitonyi GW; Njagi EC East Afr Med J; 2009 Dec; 86(12 Suppl):S58-61. PubMed ID: 21591511 [TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337 [TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus and blood transfusion. Barbara JA; Tegtmeier GE Blood Rev; 1987 Sep; 1(3):207-11. PubMed ID: 2844331 [TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Vamvakas EC Transfus Med Rev; 2002 Oct; 16(4):304-14. PubMed ID: 12415516 [TBL] [Abstract][Full Text] [Related]
34. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Noble S; Faulds D Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203 [TBL] [Abstract][Full Text] [Related]
35. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976 [TBL] [Abstract][Full Text] [Related]
36. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Winston DJ; Gale RP Bone Marrow Transplant; 1991 Jul; 8(1):7-11. PubMed ID: 1655140 [TBL] [Abstract][Full Text] [Related]
37. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy. Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791 [TBL] [Abstract][Full Text] [Related]
38. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522 [TBL] [Abstract][Full Text] [Related]